Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 (NCT03755804)

🧪 Interventions in This Study

• bendamustine (DRUG)
• Etoposide (DRUG)
• Doxorubicin (DRUG)
• Bleomycin (DRUG)
• Vincristine (DRUG)
• Vinblastine (DRUG)
• Prednisone (DRUG)
• Filgrastim (DRUG)
• Brentuximab Vedotin (DRUG)
• Cyclophosphamide (DRUG)
• DTIC (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Histologically confirmed, previously untreated CD30+ classical HL. (Participants are still eligible if they received limited emergent RT or steroid therapy - maximum of 7 days if within the last month or as approved by PI).
2. Age ≤ 21 years at the time of diagnosis (i.e., participants are eligible until their 22nd birthday) for low-risk and intermediate-risk
3. Age ≤ 25 years at the time of diagnosis (i.e., participants are eligible until their 26th birthday) for high-risk
4. All Ann Arbor stages.
5. Low-Risk: IA, IIA (excluding patients with "E" lesions or mediastinal bulk)
6. Intermediate-Risk: IA or IIA with "E" lesions or bulky mediastinal adenopathy (mediastinal mass to thoracic cavity ratio 33% or greater by chest radiograph) and IB, IIIA.
7. High-Risk: IIB, IIIB, IV
8. Adequate renal function based on GFR ≥ 70 ml/min/1.73m2 OR serum creatinine adjusted for age and gender as follows: Age 1 to \< 2 years: maximum serum creatinine 0.6 mg/dL for males and 0.6 mg/dL for females, Age 2 to \< 6 years: maximum serum creatinine 0.8 mg/dL for males and 0.8 mg/dL for females, Age 6 to \< 10 years: maximum serum creatinine 1 mg/dL for males and 1 mg/dL for females, Age 10 to \< 13 years: maximum serum creatinine 1.2 mg/dL for males and 1.2 mg/dL for females, Age 13 to \< 16 years: maximum serum creatinine 1.5 mg/dL for males and 1.4 mg/dL for females, Age ≥16 years: maximum serum creatinine 1.7 mg/dL for males and 1.4 mg/dL for females
9. Adequate hepatic function (total bilirubin ≤ 1.5 x ULN for age, and AST/ALT ≤ 2.5 x ULN for age).
10. Adequate hematologic criteria at baseline, unless secondary to Hodgkin disease diagnosis
11. Absolute neutrophil count (ANC) ≥1000/µL
12. Platelets ≥ 75,000/µL

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (8 Sites)

• Lucile Packard Children's Hospital Stanford University — Palo Alto, California
• St. Jude Midwest Affiliate - Peoria — Peoria, Illinois
• St. Jude Affiliate Baton Rouge Clinic (Our Lady of the Lakes Regional Medical Center) — Baton Rouge, Louisiana
• Maine Children's Cancer Program — Scarborough, Maine
• Massachusetts General Hospital — Boston, Massachusetts
• Dana Farber Cancer Institute — Boston, Massachusetts
• St. Jude Affiliate Clinic at Novant Health Hemby Children's Hospital — Charlotte, North Carolina
• St. Jude Children's Research Hospital — Memphis, Tennessee

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
• 💵 Compensation indicated: High-risk patients will receive Adcetris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxorubicin) (AEPA) and cyclophosphamide, Adcetris® (brentuximab vedotin), prednisone and Dac...

More studies in Hodgkin Lymphoma

• Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma — Detroit, Michigan
• Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors — Anchorage, Alaska
• Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) — Birmingham, Alabama
• PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma — Houston, Texas
• Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma — Salt Lake City, Utah
• Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma — Chicago, Illinois

Explore by condition: All Hodgkin Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.